{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Wockhardt overvalued or undervalued?
As of December 3, 2025, Wockhardt is considered expensive with a PE ratio of 310.74 and an EV to EBITDA of 55.48, significantly higher than its peers, indicating it is overvalued despite a strong stock return of 480.69% over the past three years.
Why is Wockhardt falling/rising?
On 03-Dec, Wockhardt Ltd’s stock price declined sharply by 5.33%, closing at ₹1,415.15, reflecting a notable reversal after two days of gains despite strong recent operating profit growth and rising investor participation.
Wockhardt Sees Robust Trading Activity Amidst Sector Outperformance
Wockhardt Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has emerged as one of the most actively traded stocks by value on 2 December 2025. The stock demonstrated notable trading volumes and value turnover, outperforming its sector peers and reflecting heightened investor interest and liquidity in the market.
Is Wockhardt technically bullish or bearish?
As of December 1, 2025, Wockhardt's technical trend is mildly bearish, influenced by bearish weekly MACD and KST indicators, despite some bullish signals from Bollinger Bands and strong long-term returns compared to the Sensex.
Wockhardt Stock Analysis: Technical Momentum and Market Assessment
Wockhardt’s recent trading activity reveals a notable shift in technical momentum, with key indicators signalling a transition from a bearish stance to a more nuanced mildly bearish outlook. The stock’s price movement, combined with mixed signals from MACD, RSI, and moving averages, offers investors a complex picture amid a volatile market backdrop.
How has been the historical performance of Wockhardt?
Wockhardt's net sales increased to 3,012.00 Cr in March 2025, up from 2,651.00 Cr in March 2023, but profitability remains a concern with a profit before tax of -16.00 Cr and a profit after tax loss of -57.00 Cr. Total liabilities rose to 7,586.00 Cr, and cash flow from operating activities was negative at -22.00 Cr, indicating ongoing financial challenges despite sales recovery.
Wockhardt Sees High-Value Trading Amidst Volatile Market Activity
Wockhardt Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has emerged as one of the most actively traded stocks by value on 1 December 2025. The stock demonstrated significant price movement and trading volume, reflecting heightened investor interest and notable liquidity in a volatile market environment.
Wockhardt Hits Day High with Strong Intraday Surge
Wockhardt recorded a notable intraday rally on 1 December 2025, reaching its highest price point of the day amid a broader positive market environment. The pharmaceutical company’s shares outpaced sector and benchmark indices, reflecting a significant shift in trading momentum after a brief period of decline.
Wockhardt’s Market Assessment Reflects Mixed Signals Amidst Financial and Technical Shifts
Wockhardt’s recent market evaluation reveals a complex interplay of financial performance and technical indicators, prompting a revision in the company’s assessment. While the pharmaceutical firm posted strong quarterly results, several long-term fundamentals and technical trends suggest a cautious outlook for investors.